Docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy for operable HER2-negative, node-positive breast cancer patients: Results from a single institution.


Surmell Z. G., Aksoy S., Dizdar O., Dede D. S., Dogan E., Arslan C., ...More

JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (SCI-Expanded) identifier